Us Bancorp \De\ Mersana Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $75.6 Billion
- Q4 2024
A detailed history of Us Bancorp \De\ transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 16,178 shares of MRSN stock, worth $12,133. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,178
Previous 16,178
-0.0%
Holding current value
$12,133
Previous $30,000
23.33%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MRSN
# of Institutions
125Shares Held
116MCall Options Held
233KPut Options Held
457K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$14.5 Million1.59% of portfolio
-
Nextech Invest Ag12.1MShares$9.05 Million3.72% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$8.5 Million2.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$6.5 Million2.94% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$6.29 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $72.9M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...